AGP Limited Secures 1st Position at BCSR Awards 2023

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Home > Products > Hertraz

Product List

Hertraz

Generic:

Trastuzumab

 

Therapeutic Class:

Antineoplastic Agent

 

Composition:

150 mg and 440 mg multi-dose vial containing powder for concentrate for solution for intravenous infusion. Reconstituted Hertraz concentrate contains 21 mg/mL of trastuzumab, a humanised IgG1 monoclonal antibody expressed in Chinese hamster ovary Cells.

 

Description:

Hertraz (Trastuzumab) is a monoclonal antibody used to treat breast cancer

 

Indications:

Metastatic Breast Cancer:

Hertraz is indicated for the treatment of adult patients with HER2 positive metastatic cancer (MBC).

Early Breast Cancer:

Hertraz is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC).

Metastatic Gastric Cancer:

Hertraz in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

 

Dosage:

Three – Weekly Schedule:
The recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose at threei ntervals is 6 mg/kg body weight, beginning three weeks after the loading units. Weekly Schedule:

The recommended initial loading dose of trastuzumab is 4 mg/kg body weight. The recommended weekly maintenance dose of trastuzumab is 2 mg/kg body weight, beginning one week after the loading dose.